CODX - Co-Diagnostics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.1300
+0.0100 (+0.89%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.1200
Open1.1300
Bid1.1500 x 2200
Ask1.1800 x 1000
Day's Range1.1000 - 1.1800
52 Week Range0.6940 - 3.7700
Volume109,254
Avg. Volume1,268,829
Market Cap19.344M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.4320
Earnings DateAug 14, 2019 - Aug 14, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Co-Diagnostics, Inc Reports Quarter on Quarter Sales Growth for Q2 2019

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the filing of its operating results on SEC Form 10-Q for the 3 month period ending June 30, 2019, a copy of which will be available on the Company’s website. Dwight Egan, Chairman and CEO of Co-Diagnostics: “This quarter brought several exciting milestones to the Company, including the beginning of domestic revenue from our mosquito abatement products and CoDx Design™ services related to our AgBio vertical, both of which we expect to increase over time. In addition, the Company maintains a strong financial position and remains debt-free.

  • Market Sentiment Around Loss-Making Co-Diagnostics, Inc. (NASDAQ:CODX)
    Simply Wall St.16 days ago

    Market Sentiment Around Loss-Making Co-Diagnostics, Inc. (NASDAQ:CODX)

    Co-Diagnostics, Inc.'s (NASDAQ:CODX): Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture...

  • GlobeNewswire17 days ago

    Co-Diagnostics, Inc. to Present Products and Services at the 2019 AACC Expo August 4-8

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be presenting at the 71st annual AACC Scientific Meeting and Clinical Lab Expo in Anaheim, California on August 4-8, 2019 and pursuing sales of Company products and services. Co-Diagnostics invites all interested parties to booth #2982, located in Hall C. The Company will use the opportunity to generate increased interest and sales in its infectious disease diagnostics vertical, and to introduce and promote the applications of their CoPrimer™ technology for next-generation sequencing, liquid biopsy cancer detection, and SNP differentiation to industry leaders.

  • GlobeNewswire19 days ago

    Co-Diagnostics, Inc. Vector Control Products Continue to Gain Acceptance Across the US

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the growing use of the Company’s Vector Smart™ NAM-W test by mosquito abatement districts to identify the presence of West Nile virus (WNV). Diseases like WNV are carried across the continent by migratory birds or other vectors, and are then transmitted to humans or livestock by mosquitoes.

  • GlobeNewswire26 days ago

    Co-Diagnostics Mosquito Testing Products Generate Buzz

    News from Co-Diagnostics, Inc. (CODX), a MedTech company with a patented platform for the development of molecular diagnostic tests, recently made CODX one of the hottest tickers of the day following the announcement of their Vector Smart North American mosquito (NAM) test. Prompted by the company’s news, an analyst from Maxim Group, who initiated coverage on CODX in April 2019, maintained a Buy rating on Co-Diagnostics Inc with the price target of $2. “Co-Diagnostics (CDI) shares are up ~45% following the announcement of the launch of its Vector Smart NAM test in North America.

  • Benzingalast month

    Signs Of A Cold Market

    My trades in Guardion Health Sciences Inc. (NASDAQ: GHSI) on Monday were just a series of surges and pullbacks that stopped me out three times before I threw in the towel. As far as what to take away from this miserable roll-call of trader misfortune, Simply remain aware of periods where you find yourself constantly running up against problems like these.

  • Benzingalast month

    A Look At Benzinga Pro's Most-Searched Tickers For July 19, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Midatech Pharma PLC (NASDAQ: MTP ) shares ...

  • GlobeNewswirelast month

    Co-Diagnostics Inc CoPrimers Provide High-Performance Detection of Cancer Mutations in Liquid Biopsy Samples

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today favorable results of a study to detect cancer mutations using its patented CoPrimer™ technology, with applications in liquid biopsy and companion diagnostic tests. Unlike invasive and more expensive tissue biopsies, liquid biopsies identify traces of cancer in a simple blood draw.

  • Benzingalast month

    A Look At Benzinga Pro's Most-Searched Tickers For July 11, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Vislink Technologies, Inc. (NASDAQ: VISL ) ...

  • GlobeNewswirelast month

    Co-Diagnostics, Inc. Launches North American Mosquito Diagnostic Product

    Salt Lake City, Utah – Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the product launch of their Vector Smart™ NAM test, used to identify the presence of West Nile virus,  St. Louis encephalitis, and western equine encephalitis in mosquito populations. Diseases like West Nile virus are carried across the continent by migratory birds or other vectors, and are then transmitted to humans or livestock by mosquitoes.

  • GlobeNewswirelast month

    Respected ‘Silicon Review’ lists Co-Diagnostics in 50 Fastest Growing Companies of 2019

    The Silicon Review’s 50 Fastest Growing Companies of the Year for 2019 features Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests. Emphasizing as a neutral source for decision makers, the publication acts as an excellent medium, allowing top level executives to share their contemporary thoughts and ideas.

  • Can We See Significant Insider Ownership On The Co-Diagnostics, Inc. (NASDAQ:CODX) Share Register?
    Simply Wall St.2 months ago

    Can We See Significant Insider Ownership On The Co-Diagnostics, Inc. (NASDAQ:CODX) Share Register?

    Every investor in Co-Diagnostics, Inc. (NASDAQ:CODX) should be aware of the most powerful shareholder groups. Large...

  • Business Wire2 months ago

    Co-Diagnostics, Inc. Announces New Additions to Board of Directors

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Dr. Eugene Durenard and Mr. Ted Murphy have joined the Board of Directors of Co-Diagnostics, and will serve on the Board’s Compensation and Corporate Governance/Nominating Committees and Audit Committees as independent directors. Dr. Durenard brings a thorough multi-asset class investment and entrepreneurial experience spanning 20 years to the Board of Directors.

  • GlobeNewswire2 months ago

    MedTech Outlook Names Co-Diagnostics Inc as Top 10 In-Vitro Diagnostic Provider for 2019

    MedTech Outlook’s 2019 Top 10 In-Vitro Diagnostics providers have been announced, including Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests and client of BDA International.

  • Business Wire2 months ago

    Co-Diagnostics, Inc. Launches CE-Marked Multiplex Test at CARPHA 2019

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the launch of their Logix Smart™ ZDC multiplex test at the 64th Annual 2019 Caribbean Public Health Agency (CARPHA) Health Research Conference. Its performance confirms the heightened specificity provided by the Company’s CoPrimer™ platform in multiplex PCR applications. Co-Diagnostics received CE mark approval for their ZDC multiplex test after validating its performance, which allows the diagnostic to be sold throughout the European Community, Latin America, the Caribbean Basin, as well as any other jurisdiction that accepts a CE mark as valid regulatory approval.

  • GlobeNewswire3 months ago

    CODX Reports Initial Domestic Sales Following Release of Q1 Numbers

    Molecular diagnostics company Co-Diagnostics (CODX) reported initial sales in the US from its vector control program last week, an encouraging sign that they are able to execute their business model and generate revenue following the release of quarterly results that were generally poorly received by the market. The sales announcement included reports that they have sold two laboratory packages—which are priced at $15,000-$25,000 according to their website—with more sales agreements expected before the end of June.

  • Business Wire3 months ago

    Co-Diagnostics, Inc. Announces US Sales of Vector Control Laboratory Packages and Tests

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it has entered into two sales agreements for mosquito abatement laboratory equipment and mosquito tests, and expects additional sales agreements before the end of the quarter. Co-Diagnostics CEO Dwight Egan remarked, “We are pleased to report initial sales of our mosquito vector control equipment and reagents in the United States, as forecast in the press release following our most recent 10-Q filing. Mosquito abatement departments exist in cities and counties across the country.

  • Imagine Owning Co-Diagnostics (NASDAQ:CODX) And Wondering If The 47% Share Price Slide Is Justified
    Simply Wall St.3 months ago

    Imagine Owning Co-Diagnostics (NASDAQ:CODX) And Wondering If The 47% Share Price Slide Is Justified

    It's easy to match the overall market return by buying an index fund. While individual stocks can be big winners...

  • Business Wire3 months ago

    Co-Diagnostics, Inc Files Q1 2019 Report on Form 10-Q and Updates Corporate Developments

    Co-Diagnostics, Inc. , a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the filing of its operating results on SEC Form 10-Q for the 3 month period ending March 31, 2019 and provided updates on corporate developments.

  • GlobeNewswire3 months ago

    H.C. Wainwright and Maxim Group Estimate Nearly 95% Upside for CODX

    Analysts from H.C. Wainwright and Maxim Group have both given BDA International client company Co-Diagnostics (CODX) a “Buy” rating in the past few weeks, with an estimated price target nearly double its previous close of $1.03. The reports included an in-depth analysis of the molecular diagnostics company’s technology, the quality and novelty of their intellectual property, its validation by the LGC partnership, and solutions that it will provide for various diagnostics markets (e.g.

  • GlobeNewswire3 months ago

    CEO Today Magazine Features Exclusive Interview with Co-Diagnostics Inc CEO Dwight Egan

    The May 2019 issue of the prestigious CEO Today Magazine will include an interview with the CEO of Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, and client of BDA International. The interview provides details on a variety of subjects, including a layman’s explanation of how polymerase chain reaction (PCR) works, the PCR technologies used by the Company, and their applications (liquid biopsy/early cancer detection, AgBio production, and next generation DNA sequencing, in addition to infectious disease diagnostics).  Mr. Egan also describes how their proprietary platform lowers overheads and creates cost savings passed on to the end users.

  • Business Wire4 months ago

    Co-Diagnostics, Inc. Files Provisional Patent for Simplified Targeted NGS Library Preparation

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced today the filing of a provisional patent with the USPTO for its single-step next generation sequencing (NGS) library preparation methods and composition, claiming an exclusive privilege and/or right to practice the invention, which also embodies the use of the Company’s patented CoPrimer™ technology in the process. The technology has numerous applications in liquid biopsy and oncology, agrigenomics, and infectious diseases. NGS is a powerful DNA sequencing technology enabling the mapping or identifying of a large number of DNA fragments simultaneously.

  • GlobeNewswire4 months ago

    Diagnostics Manufacturing Facility Launches in India to Service Growing Indian Healthcare Market

    The long-awaited molecular diagnostics manufacturing facility for the Indian joint venture between Co-Diagnostics Inc. and Synbiotics Pvt Ltd has finally launched, according to news released last week. BDA International client company Co-Diagnostics first announced the formation of the CoSara Diagnostics Pvt Ltd joint venture with Synbiotics in 2017. Since that time, shareholders have been eager for any news or updates concerning the completion of the facility that was described as one of the first of its kind in India, and is expected to provide molecular diagnostics across the country of India (nearly 18% of the world’s population, and expected to grow into the world’s largest single healthcare market in the next several years).

  • Business Wire4 months ago

    Co-Diagnostics, Inc. CEO Inaugurates Manufacturing Joint Venture Facility

    Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today the inauguration of its Indian joint venture facility for manufacturing in Ranoli, India. The manufacturing facility for CoSara Diagnostics Pvt Ltd (CoSara) is one of the first facilities for manufacturing molecular diagnostics in India and is intended to meet both current and future requirements for medical device manufacturing, which are expected to be implemented by the Indian government over the next few years.

  • ACCESSWIRE4 months ago

    Co-Diagnostics FY2018 Updates Include Revenue, Patents, Regulatory Clearance

    NEW YORK, NY / ACCESSWIRE / April 4, 2019 / Commercial sales of Co-Diagnostics, Inc., (CODX) products to Indian distributors commenced earlier this year, according to news released this week following the submission of their annual 10-K SEC filing for FY2018. The sales in India consisted of primer sets for the non-clinical identification of tuberculosis, malaria, and human papillomavirus (HPV), engineered using Co-Diagnostics' proprietary design process and patented CoPrimer technology, as well as other test reagents and components used in polymerase chain reaction (PCR) testing. The release did not include the amount of revenue since the sales took place in 2019, but that information should be publicly available following their Q1 SEC filing.